CA4 and neoplasm: In terms of targeted therapy, Huang et al. discovered a highly selective FTO inhibitor, meclofenamic acid (MA), which can compete with FTO for its binding site and increase m6A modification to inhibit tumour progression [141].In addition, carbonic anhydrase IV (CA4) can inhibit the Wnt pathway by targeting WTAP, thereby inhibiting tumour cell proliferation and inducing cell cycle arrest in colon cancer [142].